BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2571 related articles for article (PubMed ID: 11592358)

  • 1. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
    Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B;
    J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.
    Kremer J; Genovese M; Cannon GW; Caldwell J; Cush J; Furst DE; Luggen M; Keystone E; Bathon J; Kavanaugh A; Ruderman E; Coleman P; Curtis D; Kopp E; Kantor S; Weisman M; Waltuck J; Lindsley HB; Markenson J; Crawford B; Fernando I; Simpson K; Strand V
    J Rheumatol; 2004 Aug; 31(8):1521-31. PubMed ID: 15290730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
    Kalden JR; Scott DL; Smolen JS; Schattenkirchner M; Rozman B; Williams BD; Kvien TK; Jones P; Williams RB; Oed C; Rosenburg R;
    J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V; Tugwell P; Bombardier C; Maetzel A; Crawford B; Dorrier C; Thompson A; Wells G
    Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group.
    Tugwell P; Wells G; Strand V; Maetzel A; Bombardier C; Crawford B; Dorrier C; Thompson A
    Arthritis Rheum; 2000 Mar; 43(3):506-14. PubMed ID: 10728742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate.
    Wolfe F; Michaud K; Stephenson B; Doyle J
    J Rheumatol; 2003 Aug; 30(8):1725-32. PubMed ID: 12913927
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leflunomide, a new disease-modifying drug for treating active rheumatoid arthritis in methotrexate-controlled phase II clinical trial.
    Bao C; Chen S; Gu Y; Lao Z; Ni L; Yu Q; Xu J; Li X; Liu J; Sun L; He P; Ma J; Xu S; Ding C
    Chin Med J (Engl); 2003 Aug; 116(8):1228-34. PubMed ID: 12935395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
    Poór G; Strand V;
    Rheumatology (Oxford); 2004 Jun; 43(6):744-9. PubMed ID: 15026583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
    Khanna D; Park GS; Paulus HE; Simpson KM; Elashoff D; Cohen SB; Emery P; Dorrier C; Furst DE
    Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial.
    O'Dell JR; Leff R; Paulsen G; Haire C; Mallek J; Eckhoff PJ; Fernandez A; Blakely K; Wees S; Stoner J; Hadley S; Felt J; Palmer W; Waytz P; Churchill M; Klassen L; Moore G
    Arthritis Rheum; 2002 May; 46(5):1164-70. PubMed ID: 12115219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
    Kalden JR; Schattenkirchner M; Sörensen H; Emery P; Deighton C; Rozman B; Breedveld F
    Arthritis Rheum; 2003 Jun; 48(6):1513-20. PubMed ID: 12794818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate.
    Lu LJ; Bao CD; Dai M; Teng JL; Fan W; Du F; Yang NP; Zhao YH; Chen ZW; Xu JH; He PG; Wu HX; Tao Y; Zhang MJ; Han XH; Li XF; Gu JR; Li JH; Yu H
    Arthritis Rheum; 2009 Jul; 61(7):979-87. PubMed ID: 19565542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study.
    Flendrie M; Creemers MC; Welsing PM; van Riel PL
    Rheumatology (Oxford); 2005 Apr; 44(4):472-8. PubMed ID: 15598707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
    Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
    Lehman AJ; Esdaile JM; Klinkhoff AV; Grant E; Fitzgerald A; Canvin J;
    Arthritis Rheum; 2005 May; 52(5):1360-70. PubMed ID: 15880810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized study.
    Luis M; Pacheco-Tena C; Cazarín-Barrientos J; Lino-Pérez L; Goycochea MV; Vazquez-Mellado J; Burgos-Vargas R
    Arthritis Rheum; 1999 Oct; 42(10):2160-5. PubMed ID: 10524688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 129.